Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.’s share was trading at $47.08 as of June 8th. TVTX’s forward P/E was 63.29 according to Yahoo Finance.
Nestor Rizhniak/Shutterstock.com
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. TVTX is presented as transitioning decisively into a profitability inflection phase, driven by accelerating commercial execution of FILSPARI and emerging pipeline optionality across rare kidney diseases.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The company’s Q1 2026 results reinforce a strengthening demand trajectory, with FILSPARI U.S. net sales reaching $105.2 million, up 88% year-over-year, marking its first quarter above the $100 million threshold on a standalone basis.
Growth momentum is further supported by record patient demand in IgAN, with 993 new patient start forms versus prior highs, indicating that REMS-related prescribing friction is increasingly absorbed and demand remains intact despite regulatory complexity. The FSGS launch adds a second growth vector, with immediate reimbursed prescriptions and patient start forms recorded within days of approval, signaling meaningful pent-up demand in a previously untreated indication.
Importantly, Travere delivered its first non-GAAP profitable quarter, reporting $4.1 million in net income versus a $16.9 million loss a year earlier, reflecting a $21 million year-over-year swing and earlier-than-expected operating leverage versus prior 2027 profitability expectations. Although GAAP losses persist due to royalty obligations and stock-based compensation, underlying economics are improving as scale expands.
The business continues to generate strong gross contribution from FILSPARI despite a 15–17% Ligand royalty drag, while still demonstrating improving cash discipline with operating burn trending stable and liquidity of roughly $265 million, supplemented by milestone inflows that extend runway beyond 12 months.
Pipeline upside remains significant, with pegtibatinase re-dosing underway and HARMONY readout expected in 2H 2027, offering additional long-term optionality. Key upcoming catalysts include NKF clinical data in May 2026, Japan filing progress through partner Chugai in 2026, and continued expansion across IgAN and FSGS. Overall, Travere is positioned as a high-growth rare disease platform with accelerating profitability, multiple near-term catalysts, and a structurally improving commercial base, with upside potential driven by continued FILSPARI scaling and long-dated pipeline value realization.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy commercialization, strong pricing power, and pipeline expansion into in vivo editing and CAR-T with up to 230%+ upside potential. CRSP’s stock price has appreciated by approximately 25.94% since our coverage. Biotech Distilled shares a similar view but emphasizes Travere’s profitability inflection and FILSPARI-led commercial acceleration in rare kidney disease markets.
Travere Therapeutics, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held TVTX at the end of the first quarter which was 47 in the previous quarter. While we acknowledge the risk and potential of TVTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TVTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
